Clinic Case of Rare Type VI Osteogenesis Imperfecta
Olga N. Ignatovich,
Leyla S. Namazova-Baranova,
Tea V. Margieva,
Natalia V. Zhurkova,
Kirill V. Savostyanov,
Alexander V. Pushkov https://doi.org/10.15690/pf.v16i1.2001
Abstract
Osteogenesis imperfect is genetically heterogeneous group of diseases which are characterized by bone brittleness and fractures. It was thought for a long time that this is happening due to mutations in collagen genes. However, within past decade the understanding of osteogenesis imperfecta etiology has changed as a result of genetics development. The majority of all cases is related to mutations in collagen genes whereas rare mostly recessive forms are related to mutations in genes encoding collagen post-translational modification. Mutations in SERPINF1 gene were chosen as molecular cause of osteogenesis imperfecta type VI in 2011. Thus the new pathophysiology of this disease was revealed. Children with osteogenesis imperfecta type VI have high-frequency of fractures despite the management with bisphosphonates because mineralized bone osteoid is considerably reduced.
Keywords
Supporting agencies: Not specified
About the Authors
Olga N. Ignatovich
National Medical Research Center of Children’s Health
Russian Federation
Moscow
Russian Federation
Moscow
Leyla S. Namazova-Baranova
Pirogov Russian National Research Medical University;
Central Clinical Hospital of the Russian Academy of Sciences
Russian Federation
Moscow
Russian Federation
Moscow
Tea V. Margieva
National Medical Research Center of Children’s Health
Russian Federation
Moscow
Russian Federation
Moscow
Natalia V. Zhurkova
National Medical Research Center of Children’s Health
Russian Federation
Moscow
Russian Federation
Moscow
Kirill V. Savostyanov
National Medical Research Center of Children’s Health
Russian Federation
Moscow
Russian Federation
Moscow
Alexander V. Pushkov
National Medical Research Center of Children’s Health
Russian Federation
Moscow
Russian Federation
Moscow
References
1. Forlino A, Cabral WA, Barnes AM, Marini JC. New perspectives on osteogenesis imperfecta. Nat Rev Endocrinol. 2011;7(9):540–557. doi: 10.1038/nrendo.2011.81.
2. Bardai G, Moffatt P, Glorieux FH, Rauch F. DNA sequence analysis in 598 individuals with a clinical diagnosis of osteogenesis imperfecta: diagnostic yield and mutation spectrum. Osteoporos Int. 2016;27(12):3607–3613. doi: 10.1007/s00198-016-3709-1.
3. Sillence DO, Senn A, Danks DM. Genetic heterogeneity in osteogenesis imperfecta. J Med Genet. 1979;16(2):101–116. doi: 10.1136/jmg.16.2.101.
4. Van Dijk FS, Sillence DO. Osteogenesis imperfecta: clinical diagnosis, nomenclature and severity assessment. Am J Med Genet A. 2014;164A:1470–1481. doi: 10.1002/ajmg.a.36545.
5. Marini JC, Blissett AR. New genes in bone development what’s new in osteogenesis imperfecta. J Clin Endocrinol Metab. 2013;98:3095–3103. doi: 10.1210/jc.2013-1505.
6. Bodian DL, Chan T-F, Poon A, et al. Mutation and polymorphism spectrum in osteogenesis imperfecta type II: implications for genotype–phenotype relationships. Hum Mol Genet. 2009;18(3):463– 471. doi: 10.1093/hmg/ddn374.
7. Harrington J, Sochett E, Howard A. Update on the evaluation and treatment of osteogenesis imperfecta. Pediatr Clin North Am. 2014;61(6):1243–1245. doi: 10.1016/j.pcl.2014.08.010.
8. Fratzl-Zelman N, Misof BM, Roschger P, Klaushofer K. Classification of osteogenesis imperfecta. Wien Med Wochenschr. 2015;165(13–14):264–270. doi: 10.1007/s10354-015-0368-3.
9. Home/OMIM/NCBI. [Accessed 18 Feb 2015] Available from: https://www.ncbi.nlm.nih.gov/omim.
10. Shapiro JR. Clinical and genetic classification of osteogenesis imperfecta and epidemiology. In: Shapiro JR, Byers PH, Glorieux FH, Sponsellor PD, eds. Osteogenesis Imperfecta: a translational approach to brittle bone disease. Elsevier; 2014. рр. 15–22. doi: 10.1016/B978-0-12-397165-4.00002-2.
11. Glorieux FH, Ward LM, Rauch F, et al. Osteogenesis imperfecta type VI: a form of brittle bone disease with a mineralization defect. Bone Miner Res. 2002;17(1):30–38. doi: 10.1359/jbmr.2002.17.1.30.
12. Trejo P, Rauch F, Ward L. Hypercalcemia and hypercalciuria during denosumab treatment in children with osteogenesis imperfecta type VI. J Musculoskelet Neuronal Interact. 2018;18(1):76–80.
13. Homan EP, Rauch F, Grafe I, et al. Mutations in SERPINF1 cause osteogenesis imperfecta type VI. J Bone Miner Res. 2011;(26):2798– 2803. doi: 10.1002/jbmr.487.
14. Becker J, Semler O, Gilissen C, et al. Exome sequencing identifies truncating mutations in human SERPINF1 in autosomal-recessive osteogenesis imperfecta. Am J Hum Genet. 2011;(88):362–371. doi: 10.1016/j.ajhg.2011.01.015.
15. Semler O, Netzer C, Hoyer-Kuhn H, et al. First use of the RANKL antibody denosumab in osteogenesis imperfect type VI. J Musculoskelet Neuronal Interact. 2012;12(3):183–188.
16. Akiyama T, Dass CR, Shinoda Y, et al. PEDF regulates osteoclasts via osteoprotegerin and RANKL. Biochem Biophys Res Commun. 2009;391:789–194. doi: 10.1016/j.bbrc.2009.11.139.
17. Barros ER, Saraiva GL, de Oliveira TP, Lazaretti-Castro M. Safety and efficacy of a 1-year treatment with zoledronic acid compared with pamidronate in children with osteogenesis imperfect. J Pediatr Endocrinol Metab. 2012;25(5–6):485–491. doi: 10.1515/jpem-2012-0016.
18. Bishop N, Adami S, Faisal S, et al. Risedronate in children with osteogenesis imperfecta: a randomised, double-blind, placebo controlled trial. Lancet. 2013;382 (Issue 9902):1424–1432. doi: 10.1016/S0140-6736(13)61091-0.
19. Letocha AD, Cintas HL, Troendle JF, et al. Controlled trial of pamidronate in children with types III and IV osteogenesis imperfecta confirms vertebral gains but not short-term functional improvement. J Bone Miner Res. 2005,20:977–986. doi: 10.1359/JBMR.050109.
20. Iqbal J, Sun L, Zaidi M. Denosumab for the treatment of osteoporosis. Curr Osteoporos Rep. 2010;8:163–167. doi: 10.1007/s11914-010-0034-z.
21. Rauch F, Glorieux FH. Osteogenesis imperfecta. Lancet. 2004;363:1377–1385. doi: 10.1016/s0140-6736(04)16051-0.
22. Rauch F, Husseini A, Roughley P, et al. Lack of circulating pigment epithelium-derived factor is a marker of osteogenesis imperfecta type VI. J Clin Endocrinol Metab. 2012;97(8):E1550–1556. doi: 10.1210/jc.2012-1827.
23. Venturi G, Gandini A, Monti E, et al. Lack of expression of SERPINF1, the gene coding for pigment epithelium-derived factor, causes progressively deforming osteogenesis imperfecta with normal type I collagen. J Bone Miner Res. 2012;27(3):723–728. doi: 10.1002/jbmr.1480.
24. Caparrós-Martin JA, Valencia M, Pulido V, et al. Clinical and molecular analysis in families with autosomal recessive osteogenesis imperfecta identifies mutations in five genes and suggests genotypephenotype correlations. Am J Med Genet. 2013;161A(6):1354– 1369. doi: 10.1002/ajmg.a.35938.
25. Cho SY, Ki CS, Sohn YB, et al. Osteogenesis imperfecta type VI with severe bony deformities caused by novel compound heterozygous mutations in serpinf1. J Korean Med Sci. 2013;28(7):1107–1110. doi: 10.3346/jkms.2013.28.7.1107.
26. Al-Jallad H, Palomo T, Moffatt P, et al. Normal bone density and fat mass in heterozygous SERPINF1 mutation carriers. J Clin Endocrinol Metab. 2014;99(11):E2446–2450. doi: 10.1210/jc.2014-2505.
27. Minillo RM, Sobreira N, de Faria Soares M, et al. Novel deletion of SERPINF1 causes autosomal recessive osteogenesis imperfecta type VI in two Brazilian families. Mol Syndromol. 2014;5(6):268– 275. doi: 10.1159/000369108.
28. Stephen J, Girisha KM, Dalal A, et al. Mutations in patients with osteogenesis imperfecta from consanguineous Indian families. Eur J Med Genet. 2015;58(1):21–27. doi: 10.1016/j.ejmg.2014.10.001.
29. Basel D, Steiner RD. Osteogenesis imperfecta: recent findings shed new light on this once well-understood condition. Genet Med. 2009;11(6):375–385. doi: 10.1097/GIM.0b013e3181a1ff7b.
30. Rohrbach M, Giunta C. Recessive osteogenesis imperfecta: clinical, radiological and molecular findings. Am J Med Genet C Semin Med Genet. 2012;160C(3):175–189. doi: 10.1002/ajmg.c.31334.
31. Rauch F, Travers R, Parfitt AM, Glorieux FH. Static and dynamic bone histomorphometry in children with osteogenesis imperfecta. Bone. 2000;26(6):581–589. doi: 10.1016/s8756- 3282(00)00269-6.
32. Land C, Rauch F, Travers R, Glorieux FH. Osteogenesis imperfecta type VI in childhood and adolescence: effects of cyclical intravenous pamidronate treatment. Bone. 2007;40:638–644. doi: 10.1016/j.bone.2006.10.010.
33. Yakhyayeva GT, Namazova-Baranova LS, Margieva TV. New aspects of genetic basis, classification and treatment of osteogenesis imperfecta: literature review. Pediatricheskaya farmakologiya — Pediatric pharmacology. 2015;12(5):579–588. (In Russ). doi: 10.15690/pf.v12i5.1461.
Review
For citations:
Ignatovich O.N., Namazova-Baranova L.S., Margieva T.V., Zhurkova N.V., Savostyanov K.V., Pushkov A.V. Clinic Case of Rare Type VI Osteogenesis Imperfecta. Pediatric pharmacology. 2019;16(1):30-35. (In Russ.) https://doi.org/10.15690/pf.v16i1.2001
Views:
1202
Email this article 